A Phase I/II, open-label, non-randomized, multi-center, dose escalation study of olaparib in combination with eribulin mesylate to assess the safety, tolerability, and efficacy in patients with recurrent or metastatic triple-negative-type breast cancer, who have received anthracycline and taxane agents

Trial Profile

A Phase I/II, open-label, non-randomized, multi-center, dose escalation study of olaparib in combination with eribulin mesylate to assess the safety, tolerability, and efficacy in patients with recurrent or metastatic triple-negative-type breast cancer, who have received anthracycline and taxane agents

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Eribulin (Primary) ; Olaparib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Primary endpoint has been met. (Phase II: tumor response rate (RR)) as per results presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 02 Jun 2015 Results (phase 1) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top